Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P250003/S009

Embrace Hydrogel Embolic System

Instylla, Inc. · Decision date Sep 3, 2026

MEDTECHLEDGER EXPLANATIONP250003/S009

What did the FDA decide?

FDA posted a 30-Day Notice for Instylla, Inc.'s Embrace Hydrogel Embolic System under PMA supplement P250003/S009, dated September 3, 2026. The decision is recorded as OK30, and the supplement reason is a process change affecting manufacturer, sterilizer, packager, or supplier. The statement describes approval for a change in minimum packaging configuration.

This supplement does not represent a new approval of the entire system. The source statement does not identify which packaging component changed, the previous or new minimum configuration, or any associated manufacturing site. Specific information about the exact changed item is absent from the available record.

FDA approval order statement

approval for a change in minimum packaging configuration
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Cardiovascular
Decision date
Sep 3, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P250003/S009
Regulatory pathway
PMA supplement
Product code
QVG
Decision code
OK30
Decision date
Sep 3, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Embolization Agent, Vascular.

Product code
QVG
FDA device class
3

For the original device and its historical approval scope, see PMA P250003. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P250003 · Original PMA

    Embrace(TM) Hydrogel Embolic System

  2. P250003/S009 received

    Application receipt date recorded by FDA.

  3. P250003/S009 · FDA decision

    30-Day Notice

  4. P250003/S010 · Related supplement

    Embrace(TM) Hydrogel Embolic System

  5. P250003/S008 · Related supplement

    Embrace(TM) Hydrogel Embolic System

  6. P250003/S011 · Related supplement

    Embrace Hydrogel Embolic System

Timeline entries are records held by MedtechLedger for P250003. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250003

Product / regulatory recordCompanyPathwayDecision dateSource
Instylla, Inc.PMA approvalAug 5, 2025FDA
Instylla, Inc.PMA supplementOct 21, 2026FDA
Instylla, Inc.PMA supplementOct 23, 2026FDA
Instylla, Inc.PMA supplementOct 23, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Instylla, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
201 Burlington Rd., North Bldg., Bedford, MA, 01730

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records